CDC COCA Call: Additional mRNA COVID-19 Vaccines for Moderately to Severely Immunocompromised People

August 17, 2021
02:00PM - 03:00PM

All Times Eastern

Date: Tuesday, August 17, 2021
Time: 2:00 pm – 3:00 pm Eastern Time
Dial In: US: +1 669 254 5252 or +1 646 828 7666 or +1 669 216 1590 or +1 551 285 1373
Webinar ID: 160 213 0331; Passcode: 549822

The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for additional doses of mRNA COVID-19 vaccines for moderately to severely immunocompromised people. People with immunocompromising conditions or who take immunosuppressive medications or therapies are at increased risk for severe COVID-19. Studies indicate that some immunocompromised people have a reduced immune response following a primary COVID-19 vaccine series compared to vaccine recipients who are not immunocompromised. Studies have further demonstrated that an additional mRNA COVID-19 vaccine dose after an initial 2-dose primary mRNA COVID-19 vaccine series in some immunocompromised populations may enhance immune response.

During this Centers for Disease Control and Prevention Clinician Outreach and Communication Activity Call, presenters will discuss the current data on COVID-19 vaccines in immunocompromised people; the role of additional doses of mRNA COVID-19 vaccines, patients who should be considered to receive these additional COVID-19 vaccine doses, results from the August 13, 2021, Advisory Committee on Immunization Practices (ACIP) meeting, and CDC’s guidance on additional COVID-19 doses in immunocompromised people.